Paragon Wealth Strategies LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,236 shares of the company’s stock after acquiring an additional 67 shares during the quarter. Johnson & Johnson comprises approximately 0.2% of Paragon Wealth Strategies LLC’s investment portfolio, making the stock its 24th biggest position. Paragon Wealth Strategies LLC’s holdings in Johnson & Johnson were worth $928,000 at the end of the most recent reporting period.
Several other large investors have also modified their holdings of the stock. Cullinan Associates Inc. increased its position in shares of Johnson & Johnson by 3.1% during the 1st quarter. Cullinan Associates Inc. now owns 186,491 shares of the company’s stock worth $33,052,000 after purchasing an additional 5,625 shares during the last quarter. Perfromance Wealth Partners LLC increased its position in shares of Johnson & Johnson by 177.3% during the 1st quarter. Perfromance Wealth Partners LLC now owns 34,205 shares of the company’s stock worth $6,062,000 after purchasing an additional 21,869 shares during the last quarter. Claris Advisors LLC MO increased its position in shares of Johnson & Johnson by 3.1% during the 1st quarter. Claris Advisors LLC MO now owns 2,162 shares of the company’s stock worth $383,000 after purchasing an additional 66 shares during the last quarter. Gateway Advisory LLC increased its position in shares of Johnson & Johnson by 49.5% during the 1st quarter. Gateway Advisory LLC now owns 4,638 shares of the company’s stock worth $822,000 after purchasing an additional 1,536 shares during the last quarter. Finally, Redhawk Wealth Advisors Inc. increased its position in shares of Johnson & Johnson by 31.8% during the 1st quarter. Redhawk Wealth Advisors Inc. now owns 2,517 shares of the company’s stock worth $446,000 after purchasing an additional 607 shares during the last quarter. 68.78% of the stock is owned by hedge funds and other institutional investors.
Shares of JNJ opened at $178.28 on Monday. The stock has a 50-day simple moving average of $176.89 and a 200-day simple moving average of $174.14. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The stock has a market capitalization of $469.13 billion, a PE ratio of 24.03, a PEG ratio of 3.53 and a beta of 0.63. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.60 by $0.07. The business had revenue of $23.43 billion during the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $2.59 EPS. Analysts predict that Johnson & Johnson will post 10.23 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.54%. The ex-dividend date was Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s dividend payout ratio (DPR) is presently 60.92%.
In other news, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock valued at $13,895,302 in the last quarter. Company insiders own 0.35% of the company’s stock.
A number of brokerages recently issued reports on JNJ. Credit Suisse Group raised their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. Daiwa Capital Markets began coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating for the company. Citigroup lowered their target price on Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. The Goldman Sachs Group raised their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Finally, Sanford C. Bernstein cut Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their target price for the company from $180.00 to $183.00 in a report on Wednesday, March 16th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $190.67.
Johnson & Johnson Profile (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.